Member Nar	ne:	Member ID:	Member DOB:	
Drug Name:		Strength:	Directions:	
Physician Na	ame:	Physician Phone #:	Specialty:	
Physician Fa	x #: Pharn	nacy Name:	Pharmacy Phone:	
General Q	**Coi	Horizon NJ H ase (Elaprase) – Medi nplete page 1 for Initio	cal Necessity Request	
1. Wh	nat is the member's current weight	? lbs or	kg Date:	
			cm Date:	
Diagnosis l	Information (please indicate the c	liagnosis and answer th	e related questions):	
1.	Does the member have a docume □ Yes □ No	nted diagnosis of Hunt	er Syndrome (Mucopolysaccharidosis II, MPS II)?	
	o If no, what is the membe	r's diagnosis?		
2.	Has the diagnosis been confirmed	d by the following?		
	 Deficient iduronate 2-sulf presence of normal activity of 		ivity present in cells (except mature red blood cells) in the atase	
	□ Detection of pathogenic n	nutations in the IDS ge	ne by molecular genetic testing	
	□ Other (please specify)			
3.	 6 minute walk test (6-M Percent predicted force Spleen or liver volume 	nber have documentation of baseline values for one of the following? nute walk test (6-MWT) nt predicted forced vital capacity (FVC) on or liver volume for members under 5 years of age (please specify)		
4.	Is the drug being prescribed by o metabolic disorders? Yes or No		physician who specializes in the treatment of inherited	
Physician off	fice's signature*	Print	Name	

*Form must be completed and signed by physician or licensed representative from the physician's office

Rev. 11/21 HNJH Fax #: 888-567-0681 Page 1 of 2

Drug Name:	Strength:	Directions:
Physician Name:	Physician Phone #:	Specialty:
Physician Fax #:	Pharmacy Name:	Pharmacy Phone:
	Horizon NJ l Idursulfase (Elaprase) – Med **Complete page 2 only for Subse	lical Necessity Request
1. What is the	e member's diagnosis? Hunter Syndrome (Other, please specified)	Mucopolysaccharidosis II, MPS II) fy
2. Is the requ	est for dose change? Yes or No	
a. If	Yes, answer following:	
0	What is the dose requested?	
0	What was the previous dose?	
0	What is the member's current weight? What is the member's current height?	
	ember have beneficial response to therapy as cor used measurement? Yes or No	npared to pretreatment baseline values in the same
a. If	Yes, has the member had any of the following?	
	□ Reduction in spleen or liver volume (ent predicted forced vital capacity (FVC)
Physician office's sig	gnature* Prin	at Name

Rev. 11/21 HNJH Fax #: 888-567-0681 Page 2 of 2

^{*}Form must be completed and signed by physician or licensed representative from the physician's office